SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-220791"
 

Search: id:"swepub:oai:DiVA.org:uu-220791" > Plasma YKL-40 in Pa...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Tarpgaard, Line S. (author)

Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab : RESULTS from the NORDIC VII Study

  • Article/chapterEnglish2014

Publisher, publication year, extent ...

  • 2014-02-03
  • Public Library of Science (PLoS),2014
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-220791
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-220791URI
  • https://doi.org/10.1371/journal.pone.0087746DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:128302755URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with or without cetuximab. Patients and Methods: A total of 566 patients in the NORDIC VII Study were randomized 1:1:1 to arm A (Nordic FLOX), arm B (Nordic FLOX + cetuximab), or arm C (Nordic FLOX + cetuximab for 16 weeks followed by cetuximab alone as maintenance therapy). Pretreatment plasma samples were available from 510 patients. Plasma YKL-40 was determined by ELISA and dichotomized according to the age-corrected 95% YKL-40 level in 3130 healthy subjects. Results: Pretreatment plasma YKL-40 was elevated in 204 patients (40%), and median YKL-40 was higher in patients with mCRC than in healthy subjects (age adjusted, P < 0.001). Patients with elevated YKL-40 had shorter PFS than patients with normal YKL-40 (7.5 vs. 8.2 months; hazard ratio (HR) = 1.27 95% confidence interval (CI) 1.05-1.53 P = 0.013) and shorter OS (16.8 vs. 23.9 months; HR = 1.33, 1.04-1.69, P = 0.024). Multivariate Cox analysis demonstrated that elevated pretreatment YKL-40 was an independent biomarker of short OS (HR = 1.12, 1.01-1.25, P = 0.033). The ratio of the updated plasma YKL-40 (i.e. level after 1, 2, 8 weeks of treatment, and at end of treatment compared to the baseline level) was associated with OS (HR = 1.27, 1.06-1.52, P = 0.011). Conclusions: Plasma YKL-40 is an independent prognostic biomarker in patients with mCRC treated with first-line oxaliplatin-based therapy alone or combined with cetuximab.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Guren, Tormod K. (author)
  • Glimelius, BengtUppsala universitet,Institutionen för radiologi, onkologi och strålningsvetenskap(Swepub:uu)bengglim (author)
  • Christensen, Ib J. (author)
  • Pfeiffer, Per (author)
  • Kure, Elin H. (author)
  • Sorbye, Halfdan (author)
  • Ikdahl, Tone (author)
  • Yilmaz, Mette (author)
  • Johansen, Julia S. (author)
  • Tveit, Kjell Magne (author)
  • Uppsala universitetInstitutionen för radiologi, onkologi och strålningsvetenskap (creator_code:org_t)

Related titles

  • In:PLOS ONE: Public Library of Science (PLoS)9:2, s. e87746-1932-6203

Internet link

Find in a library

  • PLOS ONE (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view